New vaccine aims to shield sickle cell kids from deadly infections
NCT ID NCT07247188
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new 21-valent pneumococcal vaccine (PCV21) in 100 children and teens with sickle cell disease, aged 2 to 17. The goal is to see if it's safe and helps the body make antibodies better than the current 20-valent vaccine. Participants get one shot and are monitored for side effects and immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 21-valent pneumococcal conjugate vaccine (PCV21)
- What this could lead to
- If successful, this vaccine could provide better protection against pneumococcal infections for children with sickle cell disease, who are at high risk.
- What could go wrong
- This is a phase 3 trial, but it's still relatively small (100 participants). The new vaccine may not prove more effective than the existing one, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Site # 2140001
RECRUITINGSanto Domingo, Dominican Republic
-
Site # 2140003
RECRUITINGSanto Domingo, Dominican Republic
-
Site # 8400001
RECRUITINGNew Brunswick, New Jersey, 08901, United States
-
Site # 8400002
RECRUITINGAtlanta, Georgia, 30322, United States
-
Site # 8400003
RECRUITINGOmaha, Nebraska, 68114, United States
-
Site # 8400004
RECRUITINGHouston, Texas, 77030, United States
-
Site # 8400006
RECRUITINGAtlanta, Georgia, 30310, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Co-Designed support help parents embrace sickle cell care?
- Can community hospitals in zambia master severe disease care?
- A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?
- Can a phone app keep teens on track with sickle cell treatment?
- A common amino acid may calm sickle cell pain crises — a trial puts it to the test
- A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease